Frovocimab
Based on 1 Customer Validation
Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 96.78%
- CAS 番号: 1643672-70-1
- 分子量:146.38 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
製品説明
Isotype
Human IgG4 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
PCSK9
体外実験
Frovocimab (LY 3015014) binds to intact but not truncated PCSK9. The selective binding of Frovocimab to intact PCSK9 is related to its binding epitope, the linear sequence of amino acids 160-181 of the catalytic domain of human PCSK9, which is absent in truncated PCSK9. Frovocimab inhibits PCSK9 binding to LDLR while permitting the normal proteolytic cleavage of the bound intact PCSK9. Additionally, upon cleavage, truncated inactive PCSK9 is released from Frovocimab[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
体内実験
Frovocimab (LY 3015014; 5 mg/kg; i.v; once) decreases LDL cholesterol in monkeys and, unlike other PCSK9 mAbs, does not cause an accumulation of intact PCSK9 in serum[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male C57BL/6NTac mice injected with vector containing the NC R215A/R218A variant[1]
-
Dosage:10 mg/kg
-
Administration:i.v; once
-
Result:Caused significant PCSK9 accumulation.
-
Animal Model:Cynomolgus monkeys[1]
-
Dosage:5 mg/kg
-
Administration:i.v; once
-
Result:Decreased LDL cholesterol in monkeys.
臨床実験
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
遺伝子ID
アクセッション番号
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG4 kappa
アプリケーション
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized PCSK9 Protein, Human (HEK293, C-His, HY-P70545A) can bind Frovocimab. The EC50 for this effect is 2.837 ng/mL. -
Flow Cytometry analysis of Hela cells labelling PCSK9 (red) with Frovocimab (anti-PCSK9) (HY-P99626). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 kappa (HY-P99003, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
化学情報
-
CAS 番号 1643672-70-1
-
性状 Liquid
-
分子量 146.38 kDa
-
Color Colorless to light yellow
-
SMILES
[Frovocimab]
-
別名
LY 3015014
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
-
データシート (259 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)